Mutant calreticulin causes essential thrombocythemia.
作者信息
Shimoda Kazuya, Shide Kotaro, Kameda Takuro
机构信息
Kazuya Shimoda: Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
出版信息
Oncotarget. 2017 Sep 28;8(51):88251-88252. doi: 10.18632/oncotarget.21292. eCollection 2017 Oct 24.
Abstract
摘要
相似文献
1
Mutant calreticulin causes essential thrombocythemia.
Oncotarget. 2017 Sep 28;8(51):88251-88252. doi: 10.18632/oncotarget.21292. eCollection 2017 Oct 24.
2
Somatic mutations of calreticulin in myeloproliferative neoplasms.
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
3
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Eur J Haematol. 2015 Jan;94(1):31-6. doi: 10.1111/ejh.12389. Epub 2014 Dec 4.
4
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.
Leukemia. 2016 Feb;30(2):431-8. doi: 10.1038/leu.2015.277. Epub 2015 Oct 9.
5
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.
Am J Hematol. 2014 Aug;89(8):E121-4. doi: 10.1002/ajh.23743. Epub 2014 May 16.
6
Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ann Lab Med. 2015 Jan;35(1):22-7. doi: 10.3343/alm.2015.35.1.22. Epub 2014 Dec 8.
7
Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
Hematology. 2017 Dec;22(10):599-606. doi: 10.1080/10245332.2017.1312736. Epub 2017 Apr 13.
8
Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
J Clin Pathol. 2016 Aug;69(8):713-9. doi: 10.1136/jclinpath-2015-203498. Epub 2016 Jan 11.
9
CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.
Br J Haematol. 2015 Jan;168(1):151-3. doi: 10.1111/bjh.13076. Epub 2014 Aug 8.
10
CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
Am J Clin Pathol. 2016 Oct;146(4):431-8. doi: 10.1093/ajcp/aqw135.
本文引用的文献
1
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
Leukemia. 2017 May;31(5):1136-1144. doi: 10.1038/leu.2016.308. Epub 2016 Nov 3.
2
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Cancer Discov. 2016 Apr;6(4):368-81. doi: 10.1158/2159-8290.CD-15-1434. Epub 2016 Mar 7.
3
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Blood. 2016 Mar 10;127(10):1307-16. doi: 10.1182/blood-2015-09-671172. Epub 2016 Jan 27.
4
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Blood. 2016 Mar 10;127(10):1325-35. doi: 10.1182/blood-2015-11-681932. Epub 2015 Dec 14.
5
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Blood. 2016 Mar 10;127(10):1317-24. doi: 10.1182/blood-2015-11-679571. Epub 2015 Nov 25.
6
Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.
Blood. 2015 Jan 8;125(2):304-15. doi: 10.1182/blood-2014-04-555508. Epub 2014 Nov 13.
7
Somatic mutations of calreticulin in myeloproliferative neoplasms.
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
8
Jaks and Stats in cytokine signaling.
Stem Cells. 1997;15 Suppl 1:105-11; discussion 112. doi: 10.1002/stem.5530150814.
Zotero 插件